Сongenital infantile fibrosarcoma with a non-canonical TPM3-NTRK1 fusion transcript: a case report and a literature review
- Authors: Ivanov N.S.1, Panfyorova A.V.1, Konovalov D.M.1, Teleshova M.V.1, Bolshakov N.A.1, Shamanskaya T.V.1, Druy A.E.1, Kachanov D.Y.1
-
Affiliations:
- Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
- Issue: Vol 21, No 1 (2022)
- Pages: 110-120
- Section: CLINICAL OBSERVATIONS
- Submitted: 29.03.2022
- Accepted: 29.03.2022
- Published: 29.03.2022
- URL: https://hemoncim.com/jour/article/view/597
- DOI: https://doi.org/10.24287/1726-1708-2022-21-1-110-120
- ID: 597
Cite item
Full Text
Abstract
Infantile fibrosarcoma (IFS) is a rare malignant soft tissue tumor characterized by local invasion, a low rate of distant metastasis (1–13%), and manifestation during the first years of life. Overall survival rates range from 89 to 94%, event-free survival rates – from 81 to 84%. Classic IFS is characterized by t(12;15)(p13;q25) translocation resulting in the formation of the ETV6-NTRK3 fusion transcript. However, over the past few years, there have been numerous reports of IFS-like tumors with non-canonical genetic aberrations (BRAF, NTRK1, MET genes) whose prognosis is less predictable. Here we report a rare case of congenital IFS with involvement of subcutaneous fat, indolent course and a non-canonical TPM3-NTRK1 fusion transcript identified in the soft tissue and intradermal tumor components with different histological features. The patient’s parents gave their consent to the use of their child’s data, including photographs, for research purposes and in publications. The literature review explores modern algorithms for the diagnosis and treatment of IFS in children, including the use of new therapies, such as tropomyosin receptor kinase inhibitors, as well as algorithms for detecting NTRK1, NTRK2, NTRK3 gene rearrangements in solid neoplasms in general, and soft tissue tumors in particular.
About the authors
N. S. Ivanov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
Author for correspondence.
Email: greatinsmd@gmail.com
ORCID iD: 0000-0002-9927-8445
Nikolay S. Ivanov, a pediatrician, a resident in Pediatric Oncology
1 Samory Mashela St., Moscow 117997
Russian FederationA. V. Panfyorova
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0002-8580-3499
Moscow
Russian FederationD. M. Konovalov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0001-7732-8184
Moscow
Russian FederationM. V. Teleshova
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0003-4042-0125
Moscow
Russian FederationN. A. Bolshakov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0001-6313-6712
Moscow
Russian FederationT. V. Shamanskaya
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0002-3767-4477
Moscow
Russian FederationA. E. Druy
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0003-1308-8622
Moscow
Russian FederationD. Yu. Kachanov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0002-3704-8783
Moscow
Russian FederationReferences
Supplementary files
